Cover Story
By Matthew Bin Han Ong
A federal judge has ruled against the Health Resources and Services Administration over provider access to 340B Drug Pricing Program discounts for orphan drugs.
By Matthew Bin Han Ong
In Brief
Funding Opportunities
Drugs & Targets
Trending Stories
- Trump 2016: A look back at the 45th president’s impact on oncology
- Beyond the $500B Stargate Project: The frontier of AI in oncology beckons
- Felix Feng, GU cancer researcher who made fundamental discoveries in genomics, dies at 48
- Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills - What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - Rathmell steps down at NCI as Trump team considers candidates to replace her
Wafik El-Deiry, Harvey Risch have been interviewed